Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in South Korea / NCT07201857
Starting soon Not applicable

Peri-habilitation for Patients With Gastric Cancer

NCT07201857 · tracked via the Priya Life Science South Korea tracker
Sponsor
Korea University Anam Hospital
Phase
Not applicable
Started
2025-10-15
Last updated
2025-10-01

Condition(s) studied

Gastric Cancer (Diagnosis)Gastric Cancer PatientGastric Cancer Patients Undergoing GastrectomyGastric Cancer Patients Undergoing Minimally Invasive GastrectomyGastric Cancer Patients Undergoing Laparoscopic Gastrectomy

Investigational drug(s) / intervention(s)

nutrition education plus active supplementExercise

nutrition education plus active supplement: Nutrition Group (NUT) Participants will receive standard clinical care combined with nutrition education and protein-enriched soy milk supplementation for approximately 2 weeks before surgery and about 3 weeks after hospital discharge.

Exercise: Exercise and Nutrition Participants will receive peri-habilitation exercise training together with nutritional intervention, including carbohydrate plus protein-enriched soy milk supplementation twice daily (before and after exercise), for approximately 2 weeks before surgery and about 3 weeks after hospital discharge.

Study summary

This study aims to evaluate the clinical applicability of a peri-habilitation program in patients with gastric cancer by applying nutritional intervention for approximately two weeks before surgery and a combined exercise and nutrition intervention for about three weeks after hospital discharge, and by analyzing its effects on the prevention of postoperative complications and recovery.

Eligibility

Sex
ALL
Min age
65 Years
Max age
90 Years
Healthy volunteers
No
Inclusion Criteria: * Patients aged 65 years or older who have been diagnosed with gastric cancer and are scheduled to undergo surgical treatment or chemotherapy. Exclusion Criteria: * Patients with severe conditions who are unable to undergo the intervention prior to surgical treatment or chemotherapy. * Patients with physical (e.g., musculoskeletal) or mental disorders that make participation in or continuation of the program impossible. * Patients judged to be at risk of additional physical burden from the intervention.

Primary outcome measure(s)

  • Gait speed test — Baseline (2 weeks before surgery) Preoperative hospitalization (1-4 days before surgery) Postoperative discharge (at hospital discharge) 3 weeks after discharge 6 months after surgery
    * Time to walk 4 meters (or 3 meters) at a normal, comfortable pace. * Seconds(sec) * Lower values(seconds) indicate better performance (faster walking speed)
  • Chair stand test — Baseline (2 weeks before surgery) Preoperative hospitalization (1-4 days before surgery) Postoperative discharge (at hospital discharge) 3 weeks after discharge 6 months after surgery
    * Time to stand up and sit down 5 times from a chair without using the arms. * Seconds(sec) * Lower values(seconds) indicate better performance.
  • Balance test — Baseline (2 weeks before surgery) Preoperative hospitalization (1-4 days before surgery) Postoperative discharge (at hospital discharge) 3 weeks after discharge 6 months after surgery
    * Time maintaining balance in three positions (feet together, semi-tandem, and tandem stance). The maximum time allowed for each position is 10 seconds. * Seconds(sec) * Higher values(seconds) indicate better performance.
  • Timed up and go test — Baseline (2 weeks before surgery) Preoperative hospitalization (1-4 days before surgery) Postoperative discharge (at hospital discharge) 3 weeks after discharge 6 months after surgery
    * Time to stand up from a chair, walk 3 meters, turn around, walk back, and sit down. * Seconds(sec) * Lower values(seconds) indicate better performance.

Trial sites (1)

FacilityCityRegionStatus
Anam Hospital Seoul seongbuk-gu

More Korea University Anam Hospital trials in South Korea

NOn-inVAsive Blood Pressure Monitoring in Intracranial Aneurysm Embolization Recruiting
CART-BP Prospective Study for Hypertension Control Active, not recruiting
Surgical TreAtment for Obesity Related Disease and Onco-Metabolic Surgery Recruiting
Comparison of Pitavastatin Plus Ezetimibe Versus High-Intensity Statin Therapy on Risk of New-Onset Diabetes Mellitus Recruiting
Korean NIRS-IVUS Multicenter Registry Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07201857 on ClinicalTrials.gov ↗ ← All trials in South Korea